{
    "id": 1816,
    "name": "angiosarcoma",
    "source": "DOID",
    "definition": "A vascular cancer that derives_from the cells that line the walls of blood vessels or lymphatic vessels. [url:http\\://en.wikipedia.org/wiki/Hemangiosarcoma, url:https\\://en.wikipedia.org/wiki/Angiosarcoma, url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C3088, url:https\\://www.ncbi.nlm.nih.gov/pubmed/23327728]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "4508",
        "267"
    ],
    "termId": "DOID:0001816",
    "evidence": [
        {
            "id": 3295,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, angiosarcoma patients treated with Avastin (bevacizumab), in combination with Taxol (paclitaxel), showed no improvement in PFS and OS compared to Taxol (paclitaxel) alone and resulted in higher toxicity (PMID: 26215950).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2123,
                "therapyName": "Bevacizumab + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3717,
                    "pubMedId": 26215950,
                    "title": "Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26215950"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6244,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification achieved stable disease for six months following treatment with Votrient (pazopanib) (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6861,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, TRC105 and Votrient (pazopanib) combination therapy resulted complete response in 40% (2/5) of angiosarcoma patients (J Clin Oncol 34, 2016 (suppl; abstr 11016)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1431,
                "therapyName": "Carotuximab + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5882,
                    "pubMedId": null,
                    "title": "A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).",
                    "url": "http://meetinglibrary.asco.org/content/168705-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8317,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment resulted in partial response in 2 angiosarcoma patients (PMID: 27502708).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6602,
                    "pubMedId": 27502708,
                    "title": "Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27502708"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11078,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AGEN1884 treatment resulted in disease progression in 54% (6/11) of patients with advanced solid tumors, however, 45% (5/11) of patients continued with the study and a partial response of an 80% reduction was confirmed in one patient with angiosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 3075)).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 5695,
                "therapyName": "AGEN1884",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9069,
                    "pubMedId": null,
                    "title": "Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193189.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16628,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification developed progressive disease while on Nexavar (sorafenib) teatment (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01396408",
            "title": "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01446809",
            "title": "Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1472,
                    "therapyName": "Doxorubicin + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1471,
                    "therapyName": "Doxorubicin + Ifosfamide + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01462630",
            "title": "Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02048722",
            "title": "Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584309",
            "title": "Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 4140,
                    "therapyName": "Doxorubicin + Olaratumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02815995",
            "title": "Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02979899",
            "title": "A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1431,
                    "therapyName": "Carotuximab + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02987959",
            "title": "Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03009201",
            "title": "Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5179,
                    "therapyName": "Doxorubicin + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03282344",
            "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04028063",
            "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9314,
                    "therapyName": "AGEN1884 + AGEN2034 + Doxorubicin",
                    "synonyms": null
                }
            ]
        }
    ]
}